Cyberounds Logo
December 12, 2018 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Current and Emerging Therapies for Vulvo-vaginal Atrophy
CME credit is no longer available for this conference.
Nancy A. Phillips, M.D., and Gloria A. Bachmann, M.D.

Dr. Phillips is Clinical Assistant Professor and Dr. Bachmann is Professor, Department of Obstetrics and Gynecology, and Professor of Medicine, Interim Chair of Obstetrics/Gynecolgy, Associate Dean for Women's Health and Chief of the OB/GYN Service at Robert Wood Johnson University Hospital, and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Within the past 12 months, Dr. Phillips reports no commercial conflicts of interest and Dr. Bachmann has received grant/research support and been a consultant to Shionogi, Inc.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.

This activity is certified for women’s health, primary care (internal medicine, family practice and gynecology), endocrinology and for all HCPs interested in the treatment of patients with VVA. This CME activity has been peer-reviewed by Judi Chervenak, M.D., Associate Professor of Obtetrics & Gynecology and Women’s Health, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.

This activity is made possible by an unrestricted educational grant from Novo Nordisk


Release Date: 06/18/2013
Termination Date: 06/18/2016

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Discuss the physiology of menopausal symptoms including risk factors and associated comorbidities
  • Discuss the data emerging from recent clinical trials of prospective VVA therapies/strategies including safety, efficacy and side effects
  • Discuss the management of VVA, particularly with respect to overcoming medical professional and patient barriers to diagnosis and treatment.

 
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity